PT Kimia Farma TbkISX:KAEF -2.15%56 ROA % is 2.09% as of Mar. 2026, which is 20800% above its 10-year median of 0.01. GuruFocus rates ISX:KAEF with a GF Score™ of 56/100 and a GF Value™ of Rp581.98 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 118 Medical Distribution companies, PT Kimia Farma Tbk ranks worse than 77.12% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. PT Kimia Farma Tbk's annualizedNet Income for the quarter that ended in Mar. 2026 was Rp297,798 Mil.
PT Kimia Farma Tbk's average Total Assets over the quarter that ended in Mar. 2026 was Rp14,271,025 Mil. Therefore, PT Kimia Farma Tbk's annualized ROA % for the quarter that ended in Mar. 2026 was 2.09%.
The historical rank and industry rank for PT Kimia Farma Tbk's ROA % or its related term are showing as below:
ISX:KAEF'
s ROA % Range Over the Past 10 Years
Min: -10.78 Med: 0.01 Max: 6.65
Current: -1.08
During the past 13 years, PT Kimia Farma Tbk's highest ROA % was 6.65%. The lowest was -10.78%. And the median was 0.01%.
ISX:KAEF's ROA % is ranked worse than 77.12% of 118
companies
in the Medical Distribution industry
Industry Median: 2.215
vs ISX:KAEF: -1.08
PT Kimia Farma Tbk (ISX:KAEF) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
PT Kimia Farma Tbk ROA % Related Terms
PT Kimia Farma Tbk ROA % Historical Data
* Premium members only.
The historical data trend for PT Kimia Farma Tbk's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, PT Kimia Farma Tbk's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kimia Farma Tbk ROA % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Kimia Farma Tbk's ROA % distribution charts can be found below:
* The bar in red indicates where PT Kimia Farma Tbk's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
PT Kimia Farma Tbk (ISX:KAEF) has a ROA % of 2.09% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on PT Kimia Farma Tbk and its competitors. This is 20800% above median its historical median of 0.01. According to the industry distribution chart, PT Kimia Farma Tbk ranks #91 out of 118 companies in the Medical Distribution industry, placing it in the top 77.1%.
Is PT Kimia Farma Tbk's ROA % too high?
PT Kimia Farma Tbk's current ROA % of 2.09% is 20800% above median its 10-year median of 0.01. The Medical Distribution industry median ROA % is 2.22. PT Kimia Farma Tbk's value of 2.09% is 5.6% below this industry median. Based on the distribution chart, PT Kimia Farma Tbk ranks #91 out of 118 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, PT Kimia Farma Tbk has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Tbk's ROA % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Kimia Farma Tbk ranks #91 out of 118 companies for ROA %. This places PT Kimia Farma Tbk in the lower half of its industry. The industry median ROA % is 2.22. PT Kimia Farma Tbk's value of 2.09% is 5.6% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 2.22, PT Kimia Farma Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Distribution company?
The median ROA % among Medical Distribution companies is 2.22, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kimia Farma Tbk's current ROA % of 2.09% is 5.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on PT Kimia Farma Tbk and its competitors. For the Medical Distribution industry, the median ROA % is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kimia Farma Tbk's current ROA % is 2.09%, which is 20800% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp581.98, compared to a current price of Rp456.00 — trading 21.6% below its estimated fair value. The current ROA % is 2.09%, which is 20800% above median its 10-year median of 0.01 and 5.6% below the Medical Distribution industry median of 2.22. PT Kimia Farma Tbk's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For PT Kimia Farma Tbk (ISX:KAEF), the current ROA % is 2.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kimia Farma Tbk (ISX:KAEF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kimia Farma Tbk stock appears to be undervalued.
The current stock price of Rp456.00 is trading 21.6% below its estimated GF Value™ of Rp581.98.
GuruFocus considers PT Kimia Farma Tbk to be Modestly Undervalued.
Key valuation signals for ISX:KAEF:
ROA %: 2.09% (20800% above median its 10-year median of 0.01)
GF Value™: Rp581.98 vs. price of Rp456.00 (21.6% below fair value)
Industry Position: 5.6% below the Medical Distribution median (#91 of 118)
No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
56GF Score
Get the complete analysis for ISX:KAEF
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:KAEF has been successfully added to your 
